Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3Active not recruiting 1

Sponsor Class

NIH 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Neoplasm, Residual 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Hairy Cell 1Carcinoma, Small Cell 1Carcinoma in Situ 1

Interventions

Cyclophosphamide 910Carboplatin 787pembrolizumab 746Paclitaxel 744Bevacizumab 716Cisplatin 708Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 338Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Histamine Antagonists × Clear all
NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 21 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

NCT03554473 2025-05-09

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
37 enrolled 19 charts
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT00719472 2017-05-15

RATE

Genentech, Inc.

Phase 3 Completed
451 enrolled 11 charts
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡